Anthropic Pushes Into Biopharma With $400M Deal, Nobel Hire

Anthropic has spent the past 100 days executing an aggressive push into the life sciences sector, anchored by a $400 million acquisition of Coefficient Bio and the hiring of Nobel Prize-winning scientist John Jumper. The moves signal a significant expansion beyond the AI safety and general-purpose software work for which the company is primarily known.

What Happened

Anthropic has completed the acquisition of Coefficient Bio for $400 million, according to reporting by Endpoints News. In parallel, the company has brought on John Jumper, who shared the 2024 Nobel Prize in Chemistry for his work on protein structure prediction at DeepMind, where he led development of the AlphaFold system. Anthropic has also launched a dedicated product called Claude Science, positioned as a tool for research applications, and has disclosed that it is developing its own internal drug pipeline.

The moves were executed over approximately 100 days, according to Endpoints News, representing a concentrated effort to establish Anthropic as a player in biopharma and broader life sciences.

Background

Anthropic was founded in 2021 by Dario Amodei, Daniela Amodei, and other former OpenAI researchers, initially focusing on AI safety research and the development of its Claude family of large language models. The company has grown into one of the better-capitalised AI startups in the United States, drawing investment from Amazon and Google, among others.

John Jumper's arrival at Anthropic follows his tenure at Google DeepMind, where his team's AlphaFold model was credited with solving a longstanding problem in structural biology: predicting the three-dimensional shape of proteins from their amino acid sequences. The Nobel committee cited that work when awarding the 2024 Chemistry prize. Jumper is among the most prominent scientific hires made by any AI company in recent years.

Coefficient Bio is a life sciences company focused on applying computational methods to drug development. The terms of the acquisition beyond the reported $400 million figure were not made public in the available reporting.

What It Means in Practice

Claude Science, the product Anthropic has launched as part of this expansion, is described as a version of the Claude assistant configured for scientific research workflows. The company has not published full technical specifications or pricing for the product as of the time of this report.

The internal drug pipeline disclosed by Anthropic represents a step beyond providing software tools to pharmaceutical partners. Companies that develop their own drug candidates operate under a different regulatory and commercial framework than software vendors, subjecting them to oversight from bodies such as the U.S. Food and Drug Administration at various stages of development. Anthropic has not disclosed which therapeutic areas or disease targets its internal programs are pursuing.

The Coefficient Bio deal, if structured as a full acquisition, would bring drug discovery capabilities and personnel in-house rather than relying solely on external partnerships. Endpoints News did not report additional financial details such as milestone payments or earn-out structures.

Market Context

Anthropic's biopharma push arrives as several other major AI developers have also intensified efforts in life sciences. The sector has drawn attention from AI companies in part because biology generates large structured datasets amenable to machine learning, and because the economic value of accelerating drug discovery is substantial. Isomorphic Labs, a separate Alphabet subsidiary, and Recursion Pharmaceuticals are among the companies already operating at the intersection of AI and drug development.

Shares of Anthropic are not publicly traded. The company's most recent publicly reported valuation stood at approximately $61 billion following a funding round earlier in 2025.

Anthropic has not announced a timeline for clinical development milestones on its internal drug programs, and the company is expected to provide additional detail on Claude Science and its life sciences strategy in the coming months.